NO974824L - Arteriovenöse og venöse transplantasjonsbehandlinger, fremgangsmåter og blandinger - Google Patents

Arteriovenöse og venöse transplantasjonsbehandlinger, fremgangsmåter og blandinger

Info

Publication number
NO974824L
NO974824L NO974824A NO974824A NO974824L NO 974824 L NO974824 L NO 974824L NO 974824 A NO974824 A NO 974824A NO 974824 A NO974824 A NO 974824A NO 974824 L NO974824 L NO 974824L
Authority
NO
Norway
Prior art keywords
arteriovenous
procedures
mixtures
compounds
extracellular matrix
Prior art date
Application number
NO974824A
Other languages
English (en)
Norwegian (no)
Other versions
NO974824D0 (no
Inventor
Andrew Zalewski
Yi Shi
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of NO974824D0 publication Critical patent/NO974824D0/no
Publication of NO974824L publication Critical patent/NO974824L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO974824A 1995-04-19 1997-10-17 Arteriovenöse og venöse transplantasjonsbehandlinger, fremgangsmåter og blandinger NO974824L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/424,991 US6323184B1 (en) 1993-10-15 1995-04-19 Arteriovenous and venous graft treatments: methods and compositions
PCT/US1996/005334 WO1996032966A1 (en) 1995-04-19 1996-04-19 Arteriovenous and venous graft treatments: methods and compositions

Publications (2)

Publication Number Publication Date
NO974824D0 NO974824D0 (no) 1997-10-17
NO974824L true NO974824L (no) 1997-12-16

Family

ID=23684702

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974824A NO974824L (no) 1995-04-19 1997-10-17 Arteriovenöse og venöse transplantasjonsbehandlinger, fremgangsmåter og blandinger

Country Status (15)

Country Link
US (1) US6323184B1 (ja)
EP (1) EP0871496B1 (ja)
JP (1) JP3958362B2 (ja)
KR (1) KR19990007864A (ja)
CN (1) CN1177615C (ja)
AT (1) ATE400301T1 (ja)
AU (1) AU714658B2 (ja)
BR (1) BR9608454A (ja)
CA (1) CA2215631A1 (ja)
CZ (1) CZ295039B6 (ja)
DE (1) DE69637593D1 (ja)
HU (1) HU225244B1 (ja)
NO (1) NO974824L (ja)
PL (1) PL188628B1 (ja)
WO (1) WO1996032966A1 (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE426018T1 (de) 1997-04-10 2009-04-15 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
KR20010102992A (ko) * 1999-01-29 2001-11-17 추후보정 표적 ｒｎａ를 검출하는 비-침입적 방법
US6709465B2 (en) 1999-03-18 2004-03-23 Fossa Medical, Inc. Radially expanding ureteral device
US7368545B1 (en) 1999-09-29 2008-05-06 Diagnocure Inc. PCA3 messenger RNA species in benign and malignant prostate tissues
EP1263484B1 (en) * 2000-03-15 2007-05-16 OrbusNeich Medical, Inc. Coating which promotes endothelial cell adherence
DK2314293T3 (en) 2001-01-16 2017-04-18 Vascular Therapies Llc IMPLANTABLE DEVICE CONTAINING RESORBABLE MATERIAL MATERIAL AND RAPAMYCINE FOR PREVENTION OR TREATMENT OF VASCULOPROLIFERATIVE DISEASES
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050159378A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
WO2003070917A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
US20070270579A1 (en) * 2001-05-18 2007-11-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
WO2003000314A2 (en) 2001-06-20 2003-01-03 The Regents Of The University Of California Hemodialysis system and method
US7893248B2 (en) * 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
ES2427853T3 (es) 2003-02-07 2013-11-04 Diagnocure Inc. Procedimiento para detectar cáncer de próstata en una muestra
ES2452731T3 (es) 2003-06-19 2014-04-02 Vascular Therapies, Llc Dispositivo de cierre vascular
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
AU2008227875B2 (en) 2007-03-19 2014-06-12 Insuline Medical Ltd. Drug delivery device
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
EP2231229A1 (en) 2007-12-18 2010-09-29 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
EP2244740A1 (en) 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
RU2532893C2 (ru) 2008-11-07 2014-11-10 Инсьюлин Медикал Лтд. Устройство и способ доставки лекарственных средств
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
SE462364B (sv) 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5122048A (en) 1990-09-24 1992-06-16 Exxon Chemical Patents Inc. Charging apparatus for meltblown webs
CA2082411A1 (en) 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
AU3129993A (en) 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5756476A (en) * 1992-01-14 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell proliferation using antisense oligonucleotides
US5869462A (en) * 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1994015943A1 (en) 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against a platelet derived growth factor receptor related gene
AU6080294A (en) 1992-12-31 1994-08-15 Texas Biotechnology Corporation Antisense molecules directed against genes of the (raf) oncogene family
CA2153158A1 (en) 1993-01-07 1994-07-21 Andrew Zalewski Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
WO1994028721A1 (en) 1993-06-11 1994-12-22 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
WO1995010305A1 (en) 1993-10-15 1995-04-20 Thomas Jefferson University Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes

Also Published As

Publication number Publication date
PL323046A1 (en) 1998-03-02
DE69637593D1 (de) 2008-08-21
EP0871496A1 (en) 1998-10-21
NO974824D0 (no) 1997-10-17
CA2215631A1 (en) 1996-10-24
PL188628B1 (pl) 2005-03-31
CN1177615C (zh) 2004-12-01
CZ330297A3 (cs) 1998-03-18
BR9608454A (pt) 2002-02-05
JP3958362B2 (ja) 2007-08-15
AU5553296A (en) 1996-11-07
ATE400301T1 (de) 2008-07-15
HUP9800729A3 (en) 2000-07-28
EP0871496A4 (ja) 1998-10-21
US6323184B1 (en) 2001-11-27
HUP9800729A2 (hu) 1998-07-28
EP0871496B1 (en) 2008-07-09
HU225244B1 (en) 2006-08-28
CZ295039B6 (cs) 2005-05-18
CN1181706A (zh) 1998-05-13
KR19990007864A (ko) 1999-01-25
AU714658B2 (en) 2000-01-06
JPH11503911A (ja) 1999-04-06
WO1996032966A1 (en) 1996-10-24

Similar Documents

Publication Publication Date Title
NO974824D0 (no) Arteriovenöse og venös transplantasjonsbehandlinger, fremgangsmåter og blandinger
DE69736539D1 (de) System für eine on-line behandlung von zellulären blutbestandteilen, z.b. bluttplättchen die für therapeutische zwecke entnommen werden
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
DE69007503D1 (de) Katheter für eine präzise Verteilung von therapeutischen Flüssigkeiten.
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
NO965098L (no) Perfluoralkylketoninhibitorer av elastase og fremgangsmåter for fremstilling av disse
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE198706T1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
DE69526216D1 (de) Antifungaleverfahren und mitteln
DE69525279D1 (de) Behandlung von Leder zum Einfärben desselben, sowie gefärbtes Leder
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE69631381T2 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
ATE213163T1 (de) Verfahren zur behandlung von motorischen defiziten
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ZA964198B (en) Treatment regime for skin.
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
DE69111457D1 (de) Katheter und vorrichtung zur behandlung, insbesondere von lungenembolien.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application